1.41 USD
-0.1 (-6.62%)
We assign a fundamental rating of 3 out of 10 to BDMD. BDMD was compared to 188 industry peers in the Health Care Equipment & Supplies industry. Both the profitability and the financial health of BDMD get a neutral evaluation. Nothing too spectacular is happening here. BDMD has a expensive valuation and it also scores bad on growth.
1. Profitability
1.1 Basic Checks
In the past year BDMD was profitable.
BDMD had a negative operating cash flow in the past year.
In multiple years BDMD reported negative net income over the last 5 years.
In the past 5 years BDMD always reported negative operating cash flow.
1.2 Ratios
With an excellent Return On Assets value of 16.04%, BDMD belongs to the best of the industry, outperforming 96.28% of the companies in the same industry.
BDMD has a better Return On Equity (31.53%) than 98.94% of its industry peers.
With an excellent Return On Invested Capital value of 22.61%, BDMD belongs to the best of the industry, outperforming 98.40% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 16.04% | ||
| ROE | 31.53% | ||
| ROIC | 22.61% |
ROA(3y)11.63%
ROA(5y)N/A
ROE(3y)20.43%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
BDMD has a Profit Margin of 33.76%. This is amongst the best in the industry. BDMD outperforms 97.87% of its industry peers.
With an excellent Operating Margin value of 41.35%, BDMD belongs to the best of the industry, outperforming 100.00% of the companies in the same industry.
BDMD's Gross Margin of 88.17% is amongst the best of the industry. BDMD outperforms 96.81% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 41.35% | ||
| PM (TTM) | 33.76% | ||
| GM | 88.17% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
BDMD has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
The number of shares outstanding for BDMD has been reduced compared to 1 year ago.
Compared to 1 year ago, BDMD has a worse debt to assets ratio.
2.2 Solvency
An Altman-Z score of 2.66 indicates that BDMD is not a great score, but indicates only limited risk for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 2.66, BDMD is in the better half of the industry, outperforming 67.55% of the companies in the same industry.
A Debt/Equity ratio of 0.49 indicates that BDMD is not too dependend on debt financing.
BDMD has a Debt to Equity ratio (0.49) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.49 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 2.66 |
ROIC/WACC3.69
WACC6.12%
2.3 Liquidity
BDMD has a Current Ratio of 1.77. This is a normal value and indicates that BDMD is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 1.77, BDMD is doing worse than 68.62% of the companies in the same industry.
BDMD has a Quick Ratio of 1.74. This is a normal value and indicates that BDMD is financially healthy and should not expect problems in meeting its short term obligations.
BDMD has a Quick ratio of 1.74. This is comparable to the rest of the industry: BDMD outperforms 45.21% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.77 | ||
| Quick Ratio | 1.74 |
3. Growth
3.1 Past
BDMD shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 18.58%, which is quite good.
The Revenue has grown by 17.74% in the past year. This is quite good.
EPS 1Y (TTM)18.58%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%18.58%
Revenue 1Y (TTM)17.74%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%17.74%
3.2 Future
No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 2.94, the valuation of BDMD can be described as very cheap.
Based on the Price/Earnings ratio, BDMD is valued cheaply inside the industry as 98.94% of the companies are valued more expensively.
BDMD is valuated cheaply when we compare the Price/Earnings ratio to 25.47, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 2.94 | ||
| Fwd PE | N/A |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, BDMD is valued cheaply inside the industry as 98.94% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 2.27 |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A
5. Dividend
5.1 Amount
No dividends for BDMD!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NASDAQ:BDMD (11/21/2025, 8:13:27 PM)
1.41
-0.1 (-6.62%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners2.11%
Inst Owner ChangeN/A
Ins Owners71.59%
Ins Owner ChangeN/A
Market Cap36.04M
Revenue(TTM)37.04M
Net Income(TTM)12.50M
AnalystsN/A
Price TargetN/A
Short Float %1149.67%
Short Ratio0.68
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 2.94 | ||
| Fwd PE | N/A | ||
| P/S | 0.97 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 0.91 | ||
| P/tB | 0.91 | ||
| EV/EBITDA | 2.27 |
EPS(TTM)0.48
EY34.04%
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.36
FCFYN/A
OCF(TTM)-0.25
OCFYN/A
SpS1.45
BVpS1.55
TBVpS1.55
PEG (NY)N/A
PEG (5Y)N/A
Graham Number4.09
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 16.04% | ||
| ROE | 31.53% | ||
| ROCE | 35.34% | ||
| ROIC | 22.61% | ||
| ROICexc | 23.79% | ||
| ROICexgc | 23.82% | ||
| OM | 41.35% | ||
| PM (TTM) | 33.76% | ||
| GM | 88.17% | ||
| FCFM | N/A |
ROA(3y)11.63%
ROA(5y)N/A
ROE(3y)20.43%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.48
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.49 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 1.19 | ||
| Cap/Depr | 250.52% | ||
| Cap/Sales | 7.7% | ||
| Interest Coverage | 30.8 | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.77 | ||
| Quick Ratio | 1.74 | ||
| Altman-Z | 2.66 |
F-Score3
WACC6.12%
ROIC/WACC3.69
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)18.58%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%18.58%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)17.74%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%17.74%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y29.11%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-150.56%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-518.93%
OCF growth 3YN/A
OCF growth 5YN/A
BAIRD MEDICAL INVESTMENT HOL / BDMD FAQ
What is the ChartMill fundamental rating of BAIRD MEDICAL INVESTMENT HOL (BDMD) stock?
ChartMill assigns a fundamental rating of 3 / 10 to BDMD.
What is the valuation status for BDMD stock?
ChartMill assigns a valuation rating of 3 / 10 to BAIRD MEDICAL INVESTMENT HOL (BDMD). This can be considered as Overvalued.
How profitable is BAIRD MEDICAL INVESTMENT HOL (BDMD) stock?
BAIRD MEDICAL INVESTMENT HOL (BDMD) has a profitability rating of 5 / 10.
Can you provide the PE and PB ratios for BDMD stock?
The Price/Earnings (PE) ratio for BAIRD MEDICAL INVESTMENT HOL (BDMD) is 2.94 and the Price/Book (PB) ratio is 0.91.
What is the financial health of BAIRD MEDICAL INVESTMENT HOL (BDMD) stock?
The financial health rating of BAIRD MEDICAL INVESTMENT HOL (BDMD) is 4 / 10.